Liver Cancer News and Research

RSS

Liver cancer is more common in older people. Over half of people newly diagnosed with liver cancer are age 65 and over. Liver cancer is more common in men than in women. Liver cancer rates are highest among Asians and Pacific Islanders, most likely because of higher prevalence of viral Hepatitis infection. Liver cancer rates are lower among whites than Blacks or Asians and Pacific Islanders. At this time, we do not know exactly what causes cancer of the liver. There are several different types of liver cancer. The most common type is associated with long-term excessive alcoholic beverage use, scarring of the liver (cirrhosis), and Hepatitis B virus or Hepatitis C virus infection. Long-term use of anabolic steroids can also increase the risk of getting liver cancer. Smoking is also believed to increase the risk of getting liver cancer.

New report reveals striking variation in cancer burden within AANHPI population

A new report describes cancer among Asian Americans, Native Hawaiians, and Pacific Islanders (AANHPIs), and reports striking variation in the cancer burden within this population, reflecting vast differences in exposure to cancer risk factors.

18 Jan 2016

Salvat, Lee's Pharmaceutical partner to market Duoxal ear drops in Greater China

Laboratorios SALVAT, S.A. and Lee's Pharmaceutical (HK) Limited, a wholly-owned subsidiary of Lee's Pharmaceutical Holdings Limited, jointly announced today the signing of an exclusive License and Supply Agreement for the marketing and distribution of Duoxal ear drops (patented combination solution of Ciprofloxacin and Fluocinolone Acetonide) in the People's Republic of China, Hong Kong S.A.R., Macau S.A.R., and Taiwan and an option to add Thailand to the contractual territory.

12 Jan 2016

Cancer mortality continues to drop in the U.S.

Steady reductions in smoking combined with advances in cancer prevention, early detection, and treatment have resulted in a 23% drop in the cancer death rate since its peak in 1991. The drop translates to more than 1.7 million cancer deaths averted through 2012.

8 Jan 2016

Eliminating the 'bad seeds' of liver cancer

Researchers have found the 'bad seeds' of liver cancer and believe they could one day reprogram them to remain responsive to cancer treatment, a new study has found.

7 Jan 2016

SillaJen reports initiation of multinational randomized Phase 3 study of Pexa-Vec in HCC patients

SillaJen, Inc., a private, clinical-stage, biotherapeutics company focused on the development of oncolytic immunotherapy products for cancer, has announced the initiation of a multinational randomized Phase 3 open-label study of its lead product candidate, Pexa-Vec (formerly JX-594), in patients with advanced liver cancer, also known as hepatocellular carcinoma (HCC).

5 Jan 2016

Study unravels mechanisms by which saffron-based crocin prevents liver cancer

Liver cancer remains among the leading causes of cancer-related death worldwide. New study lead by UAE University Prof. Amr Amin unravels mechanisms by which saffron-based 'crocin' protects against liver cancer.

4 Jan 2016

YAP protein appears to play vital role in helping control inflammation inside the brain

Inside the brain, a protein called YAP, best known for its ability to help right-size our developing hearts and livers, appears to have the different but equally important task of helping control inflammation.

23 Dec 2015

SciClone plans to pursue development of SGX942 in the Greater China market

SciClone Pharmaceuticals, Inc. today announced plans to pursue development and registration of SGX942 in the Greater China market, for the treatment of oral mucositis.

21 Dec 2015

Findings show promising evidence for creating broad-spectrum antiviral

UW researchers working in collaboration with Kineta Inc. and the University of Texas at Galveston have shown that making a drug-like molecule to turn on innate immunity can induce genes to control infection in several -known viruses.

18 Dec 2015

RBHS Chancellor leads study to eliminate chronic viral hepatitis

Chronic viral hepatitis has a reputation for being a silent killer. The infection often goes undetected until the symptoms of advanced liver cancer appear. By that point, a patient has a five-year survival rate, according to the American Cancer Society.

17 Dec 2015

Prophylaxis treatment can protect children who receive liver transplants from HBV-infected donors

Researchers have found that a prophylaxis treatment can prevent new-onset hepatitis B in children who receive liver transplants from donors who were previously infected with hepatitis B virus (HBV) but had successfully cleared the virus.

16 Dec 2015

SLU scientist awarded new $2.2 million NIH grant to develop cure for hepatitis B

With proof-of-principle in his pocket and a new $2.2 million grant from the National Institutes of Health, SLU scientist John Tavis, Ph.D., will take his 25 year mission to finally develop a cure for the hepatitis B virus into the next phase.

15 Dec 2015

New therapeutic target can prevent abnormal blood vessel growth that causes gastrointestinal bleeding

A study by IRB Barcelona and IDIBAPS reveals a therapeutic target to prevent the development of the many abnormal blood vessels that cause gastrointestinal bleeding—the main complication in cirrhosis.

12 Dec 2015

Researchers discover 'triple attack' technique to target liver cancer tumors

In an interdisciplinary collaboration between prominent academic and industry investigators, researchers have discovered a novel method for repositioning an FDA-approved anti-cancer compound so it can specifically target liver cancer tumors. A 'triple attack' technique combining chemotherapy, thermal ablation, and hyperthermia provided a highly targeted, yet minimally invasive approach.

8 Dec 2015

Quest Diagnostics performs RNA testing on patient specimens to detect more cases of HCV

In its commitment to provide diagnostic insights that enhance patient care and outcomes, Quest Diagnostics will automatically perform molecular testing on all patient specimens whose antibody screening results indicate hepatitis C virus infection, and remove standalone positive antibody screening as a test option.

From Quest Diagnostics 8 Dec 2015

Can-Fite BioPharma reports financial results, provides updates on drug development programs

Can-Fite BioPharma Ltd., a biotechnology company with a pipeline of proprietary small molecule drugs being developed to treat inflammatory diseases, cancer and sexual dysfunction, today reported financial results for the nine months ended September 30, 2015 and updates on its drug development programs.

27 Nov 2015

Researchers reveal new technique to grow human hepatocytes in the laboratory

In new research appearing in the prestigious journal Nature Biotechnology, an international research team led by The Hebrew University of Jerusalem describes a new technique for growing human hepatocytes in the laboratory. This groundbreaking development could help advance a variety of liver-related research and applications, from studying drug toxicity to creating bio-artificial liver support for patients awaiting transplantations.

27 Nov 2015

Liver's cannabinoid receptors could be targeted to combat liver cancer in some patients

A new study reveals that the liver's cannabinoid receptors could be targeted to fight liver cancer in some patients; and it offers a way to predict what treatments have the best chance of working.

23 Nov 2015

Fewer than 1 in 3 UK hospitals employ full-time doctors specialized in liver medicine

Despite rising rates of alcohol- and obesity-related liver disease, fewer than 1 in 3 UK hospitals employ a full-time liver specialist

22 Nov 2015

Crucial tumor-suppressing gene protects immune attack against lung cancer

A crucial tumor-thwarting gene protects an immune attack against lung cancer by blocking the key to an off switch on T cells, the customized warriors of the immune system, a team led by researchers at The University of Texas MD Anderson Cancer Center reports in the Journal of the National Cancer Institute.

21 Nov 2015